Canary Capital’s Canary Staked INJ ETF began trading on Nasdaq under the ticker INJC on November 5, 2026, giving U.S. investors exchange-traded exposure to Injective’s native INJ token and its potential staking rewards. The issuer describes the product as the first U.S. spot staked INJ ETF. Under normal conditions, the fund plans to stake at least 90% of its INJ, while retaining reserves for redemptions, expenses and asset protection. Net staking rewards are intended to increase the fund’s assets and daily net asset value rather than provide a scheduled cash distribution. The fund charges a 1.10% annual sponsor fee, with additional staking-related fees shared among service providers, and rewards are variable and not guaranteed. The 21-day unbonding period on Injective makes the unstaked reserve important for liquidity, while shareholder transactions remain separate from the trust’s token withdrawals. BitGo serves as custodian and Flow Traders U.S. LLC is the designated liquidity provider. Canary warns that validator downtime or misconduct could cause slashing losses, and the product is not registered under the Investment Company Act of 1940. The launch follows the fund’s November 3 Form 8-A12B filing and November 2 S-1 amendment, and comes amid broader expansion of altcoin investment products.